Skip to Content

Posts tagged with "Uncategorized"

  • Cancer

    Glioblastoma Is Bad News, Period

    Everyone keeping up with the news will have heard about Sen. McCain’s diagnosis of glioblastoma multiforme (GBM). This is not good news at all; GBM is a very aggressive tumor type for which treatment options are poor. The contrast to ex-President Jimmy Carter’s brain cancer experience is stark, and many people outside the biomedical fi… Read More
  • Drug Assays

    Model This?

    Via Ash Jogalekar on Twitter, I came across this new paper from researchers at AstraZeneca (and collaborators in Sweden, the UK, and Denmark) on the synthesis and activity of some plasmin inhibitors. Plasmin is an anticoagulation target, and has a lysine-binding site in its Kringle-1 domain (yeah, that’s the real name) that is the site of… Read More
  • Business and Markets

    Following Up

    Here’s a question that I’m not sure if there’s a general answer to: if you’re putting together a drug discovery portfolio, what percentage of the projects should be new ones, and how many should be some form of follow-up? I say that there may not be a general answer because every place I’ve worked has… Read More
  • Academia (vs. Industry)

    Changes in NIH Grant Policy?

    There are some pretty big funding changes being proposed at the NIH that many people may not be aware of. A concerned NIH grantee has sent along some links and comments about these, and I think that they’re worth bringing up. Here’s a blog post by Mike Lauer of the NIH going into some details: Read More
  • Drug Assays

    Aggregator Aggravation, In a New Way

    Experienced drug discovery folks, particularly those that work early on in the process, will tell you that aggregation is one of the most common sources of false positive “hits”. This happens when the molecule in question bunches up with others of its kind and makes a larger species, particles of something that has different properties… Read More
  • Chemical Biology

    More Spring-Loaded Reagents

    I wrote just about this time last year about a new “strain-release” bond forming reaction system from the Baran group at Scripps. Now they’ve got a good-sized paper in JACS with more reactions in that line, but be warned. If you hit “Print” on the Supporting Information file, you’d better have spare paper, becaus… Read More
  • In Silico

    The Flightosome

    I got this diagram from Arjun Raj‘s Twitter feed, and I think I enjoy it a bit more every time I see it. Some of that is because it’s a big part of what I was trying to get across in this column, but I think that the sketch does a more thorough job of… Read More
  • Chemical Biology

    Curcumin Will Waste Your Time

    I really enjoyed reading this article in J. Med. Chem. on curcumin. (Update: here’s the take over at Practical Fragments). That’s a well-known natural product, found in large quantities in turmeric root (which is where most of the yellow color comes from). It has, over the years, been a hit in many, many assays, and… Read More
  • In Silico

    Watson and Pfizer

    I have wondered several times around here about how (and if) IBM’s Watson platform is going to be able to help out with drug discovery, and it looks like we may be able to find that out. Pfizer has signed up with IBM to use the Watson technology in its immuno-oncology research. Here we go: Watson… Read More
  • Chemical News

    Nitration Isn’t So Simple

    OK, let’s get physical organic here for a little while. For atat ose outside the field, physical organic chemistry is the branch that studies how and why the reactions of organic chemistry happen – the details of which bonds break and form, in what order, in what arrangement, where the atoms and electrons are moving and… Read More
...91011...